Michael Manning

1.8k total citations
44 papers, 436 citations indexed

About

Michael Manning is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Manning has authored 44 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 20 papers in Hematology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Manning's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (39 papers), Hemophilia Treatment and Research (18 papers) and Autoimmune Bullous Skin Diseases (13 papers). Michael Manning is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (39 papers), Hemophilia Treatment and Research (18 papers) and Autoimmune Bullous Skin Diseases (13 papers). Michael Manning collaborates with scholars based in United States, Germany and United Kingdom. Michael Manning's co-authors include William R. Lumry, Jonathan A. Bernstein, Donald D. Stevenson, Timothy Craig, Marc A. Riedl, David Fitts, Mark Davis‐Lorton, James Baker, Thomas Machnig and Richard Gower and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Journal of Allergy and Clinical Immunology.

In The Last Decade

Michael Manning

35 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Manning United States	12	326	131	100	98	87	44	436
Henrik Balle Boysen United States	10	664 2.0×	273 2.1×	228 2.3×	196 2.0×	77 0.9×	12	717
Zlatko Sisic United Kingdom	9	339 1.0×	158 1.2×	118 1.2×	90 0.9×	50 0.6×	18	445
Nóra Veszeli Hungary	14	355 1.1×	141 1.1×	107 1.1×	147 1.5×	57 0.7×	35	466
Daniel Soteres United States	9	168 0.5×	81 0.6×	54 0.5×	51 0.5×	35 0.4×	37	270
György Temesszentandrási Hungary	8	325 1.0×	132 1.0×	91 0.9×	113 1.2×	50 0.6×	11	375
E. Rusicke Germany	9	413 1.3×	164 1.3×	149 1.5×	147 1.5×	63 0.7×	23	449
Thomas Machnig United States	15	582 1.8×	225 1.7×	182 1.8×	195 2.0×	96 1.1×	37	626
M. Baş Germany	5	448 1.4×	226 1.7×	175 1.8×	99 1.0×	46 0.5×	7	476
Zsuzsanna Zotter Hungary	11	352 1.1×	138 1.1×	90 0.9×	123 1.3×	47 0.5×	20	409
Beáta Visy Hungary	10	563 1.7×	235 1.8×	209 2.1×	175 1.8×	77 0.9×	22	604

Countries citing papers authored by Michael Manning

Since Specialization

Citations

This map shows the geographic impact of Michael Manning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Manning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Manning more than expected).

Fields of papers citing papers by Michael Manning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Manning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Manning. The network helps show where Michael Manning may publish in the future.

Co-authorship network of co-authors of Michael Manning

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Manning. A scholar is included among the top collaborators of Michael Manning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Manning. Michael Manning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aygören‐Pürsün, Emel, Timothy Craig, Michael Manning, et al.. (2025). Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks. Allergy Asthma and Clinical Immunology. 21(1). 10–10. 1 indexed citations

Farkas, Henriette, Jonny Peter, Marcin Stobiecki, et al.. (2025). Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema. Annals of Allergy Asthma & Immunology. 135(3). 311–319.e6. 1 indexed citations

Cohn, Danny M., Florence Ida Hsu, Raffi Tachdjian, et al.. (2025). Clinical Study Experience Suggests No Impact On Hemostasis Among Patients With Hereditary Angioedema Receiving Garadacimab And Undergoing Surgical/Medical Procedures. Journal of Allergy and Clinical Immunology. 155(2). AB211–AB211.

Riedl, Marc A., Jonathan A. Bernstein, Joshua Jacobs, et al.. (2025). Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis. The Journal of Allergy and Clinical Immunology In Practice. 13(9). 2381–2389.e3. 1 indexed citations

Manning, Michael, Laura Bordone, Danny M. Cohn, et al.. (2024). PHASE 2 OPEN-LABEL EXTENSION OF DONIDALORSEN IN PATIENTS WITH HEREDITARY ANGIOEDEMA: A WEEK 197 ANALYSIS. Annals of Allergy Asthma & Immunology. 133(6). S38–S38.

Lumry, William R., Timothy Craig, John Anderson, et al.. (2023). Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis. Allergy Asthma and Clinical Immunology. 19(1). 105–105. 3 indexed citations

Lumry, William R., Bruce L. Zuraw, Marco Cicardi, et al.. (2021). Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases. 16(1). 329–329. 24 indexed citations

Manning, Michael. (2021). Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists. Dermatology and Therapy. 11(5). 1829–1838. 5 indexed citations

Levy, Donald S., Teresa Caballero, Iftikhar Hussaın, et al.. (2020). Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema. Pediatric Allergy Immunology and Pulmonology. 33(3). 136–141. 16 indexed citations

10.

Sharma, Vibha, et al.. (2020). A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy. PLoS ONE. 15(12). e0241648–e0241648. 3 indexed citations

11.

Bernstein, Jonathan A., Timothy Craig, Michael Manning, et al.. (2019). Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. Allergy Asthma and Clinical Immunology. 15(1). 13–13. 13 indexed citations

12.

Li, H. Henry, Bruce L. Zuraw, Hilary Longhurst, et al.. (2019). Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. Allergy Asthma and Clinical Immunology. 15(1). 49–49. 9 indexed citations

13.

Watson, Douglas J., Marc A. Riedl, Aleena Banerji, et al.. (2018). Use Of Central Venous Access Devices (CVAD) And Associated Outcomes In Hereditary Angioedema (HAE) Patients: Findings From A Large United States (US) Claims Database. Journal of Allergy and Clinical Immunology. 141(2). AB50–AB50. 1 indexed citations

14.

Lumry, William R., Timothy Craig, Bruce L. Zuraw, et al.. (2018). Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. The Journal of Allergy and Clinical Immunology In Practice. 6(5). 1733–1741.e3. 67 indexed citations

15.

Riedl, Marc A., Aleena Banerji, Michael Manning, et al.. (2018). Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. Orphanet Journal of Rare Diseases. 13(1). 180–180. 15 indexed citations

16.

Riedl, Marc A., Aleena Banerji, Michael Manning, et al.. (2017). Intravenous C1-INH [C1-INH(IV)] Use Among Patients with Hereditary Angioedema (HAE) in the United States (US) and Associated Health Care Resource Utilization (HCRU). Journal of Allergy and Clinical Immunology. 139(2). AB231–AB231.

17.

Bernstein, Jonathan A., Michael Manning, Henry Li, et al.. (2013). Escalating Doses of C1 Esterase Inhibitor (CINRYZE) for Prophylaxis in Patients With Hereditary Angioedema. The Journal of Allergy and Clinical Immunology In Practice. 2(1). 77–84.e1. 39 indexed citations

18.

Lumry, William R., Michael Manning, David Hurewitz, et al.. (2013). Nanofiltered C1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks due to C1-Inhibitor Deficiency in Children. The Journal of Pediatrics. 162(5). 1017–1022.e2. 46 indexed citations

19.

Schranz, Jennifer, Robyn J. Levy, William R. Lumry, et al.. (2012). Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology. 129(2). AB369–AB369. 4 indexed citations

20.

Wenzel, Sally E., William R. Lumry, Michael Manning, et al.. (1998). Efficacy, Safety, and Effects on Quality of Life of Salmeterol Versus Albuterol in Patients with Mild to Moderate Persistent Asthma. Annals of Allergy Asthma & Immunology. 80(6). 463–470. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact